Crossmark

TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling

Published Online: 2024-05-21

Authors

Zheng, Di

Ning, Jinzhuo

Deng, Hao

Ruan, Yuan

Cheng, Fan http://orcid.org/0000-0002-3471-6221
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82370765, 82100806)

key laboratory open project of Hubei Province (2021KFY039)
License Information

Text and Data Mining valid from 2024-05-21

Version of Record valid from 2024-05-21
More Information

Article History

Received: 29 January 2024

Accepted: 4 May 2024

First Online: 21 May 2024

Declarations

:

: The experiment with patient tissue specimens was authorized by the Ethics Committee of Renmin Hospital of Wuhan University. All animal experiments were approved by the Animal Care and Use Committee of Wuhan University Renmin Hospital.

: All authors have approved the publication of this study.

: The authors declare no conflict of interest.

Document is current